The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2025 | Practical advice for treating steroid-refractory chronic GvHD
In this video, Dennis Kim, MD, PhD, Princess Margaret Cancer Centre, Toronto, Canada, shares practical advice for physicians treating steroid-refractory chronic graft-versus-host disease (GvHD). Dr Kim emphasizes the importance of early intervention and switching to next-line therapies promptly to prevent further tissue damage, which could worsen patient outcomes. This interview took place at the 51st Annual Meeting of the EBMT in Florence, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So I think that what I would like to emphasize is that probably you are better off starting earlier without delaying their treatment as well as switching to their next line of therapy. So whenever you delay the switch of your treatment to the next line of therapy, then it will make more tissue damage in the patient suffering from chronic GVHD, which will decrease their response rate and which will also deteriorate their clinical outcomes...
So I think that what I would like to emphasize is that probably you are better off starting earlier without delaying their treatment as well as switching to their next line of therapy. So whenever you delay the switch of your treatment to the next line of therapy, then it will make more tissue damage in the patient suffering from chronic GVHD, which will decrease their response rate and which will also deteriorate their clinical outcomes. So my suggestion would be that you have to try to assess your patient as often as you can so that you can move on to the next line of therapy as much as you can.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Honoraria: Sanofi, Novartis, Astellas, Pfizer, Sankyo-Daichi, Jazz.
